Literature DB >> 10227331

Biology of IL-5 in health and disease.

T Lalani1, R K Simmons, A R Ahmed.   

Abstract

LEARNING
OBJECTIVES: Reading this article will increase the readers' knowledge of the biology of interleukin-5 (IL-5), an important cytokine. The immune and inflammatory responses of any organism are the basis of the defense mechanism ensuring its survival. The role of IL-5 in these processes, as well as in the pathogenesis of various diseases has been discussed along with the effects of various pharmacologic agents on the production and function of IL-5. DATA SOURCES: A detailed literature search was performed. Studies considered relevant and important, in all languages, which involved humans and animals were used. STUDY SELECTION: Information was obtained only from peer reviewed journals.
RESULTS: Interleukin-5 is normally produced by T-cells, mast cells, and eosinophils while Reed Sternberg and Epstein Barr virus (EBV) transformed cells also produce IL-5. Monoclonal antibodies (mAb) to IL-5 are potent inhibitors of IL-5 mediated tissue damage, secondary to eosinophil infiltration. The majority of the studies on IL-5 are preliminary, often the information is obtained from animal studies or in vitro systems and occasionally from pathologic tissue analysis. This along with the absence of confirmatory studies is a limiting factor. Nonetheless, the role of IL-5 in allergic and immunologic disease and asthma may be central to their pathogenesis.
CONCLUSIONS: Interleukin-5 is an important molecule that is participant to many processes that maintain health and are involved directly or indirectly in the pathogenesis of disease. Some pharmacologic agents can modify IL-5 production in vivo. Development of selective inhibitors of IL-5 may have a potential use for specific therapy of certain autoimmune, inflammatory, and neoplastic diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227331     DOI: 10.1016/S1081-1206(10)63281-4

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  9 in total

Review 1.  Update on reslizumab for eosinophilic asthma.

Authors:  Juan Carlos Cardet; Elliot Israel
Journal:  Expert Opin Biol Ther       Date:  2015       Impact factor: 4.388

2.  A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.

Authors:  Patricia Price; Niamh M Keane; Silvia Lee; Andrew F Y Lim; Elizabeth J McKinnon; Martyn A French
Journal:  Immunology       Date:  2006-06-22       Impact factor: 7.397

Review 3.  Innate and adaptive immunity to the nematode Strongyloides stercoralis in a mouse model.

Authors:  Sandra Bonne-Année; Jessica A Hess; David Abraham
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

4.  Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes.

Authors:  Sheng-Li Ji; Hui-Fei Cui; Feng Shi; Yan-Qing Chi; Ji-Chao Cao; Mei-Yu Geng; Hua-Shi Guan
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

5.  Update on strongyloidiasis in the immunocompromised host.

Authors:  Luis A Marcos; Angélica Terashima; Marco Canales; Eduardo Gotuzzo
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

6.  Genome-wide expression profiles identify potential targets for gene-environment interactions in asthma severity.

Authors:  Joanne E Sordillo; Roxanne Kelly; Supinda Bunyavanich; Michael McGeachie; Weiliang Qiu; Damien C Croteau-Chonka; Manuel Soto-Quiros; Lydiana Avila; Juan C Celedón; John M Brehm; Scott T Weiss; Diane R Gold; Augusto A Litonjua
Journal:  J Allergy Clin Immunol       Date:  2015-04-24       Impact factor: 10.793

Review 7.  Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma.

Authors:  Steven R Barthel; Mats W Johansson; Dawn M McNamee; Deane F Mosher
Journal:  J Leukoc Biol       Date:  2007-10-10       Impact factor: 4.962

8.  The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice.

Authors:  Jessica A Hess; Bin Zhan; April R Torigian; John B Patton; Nikolai Petrovsky; Tingting Zhan; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  PLoS Negl Trop Dis       Date:  2016-07-07

Review 9.  Host Immunity and Inflammation to Pulmonary Helminth Infections.

Authors:  Jill E Weatherhead; Pedro Gazzinelli-Guimaraes; John M Knight; Ricardo Fujiwara; Peter J Hotez; Maria Elena Bottazzi; David B Corry
Journal:  Front Immunol       Date:  2020-10-20       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.